Skip to main navigation
Syndax
  • Home
  • About Us
    • Back
    • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Patients & Caregivers
  • Pipeline
    • Back
    • Pipeline
    • Entinostat
    • SNDX-6352
    • SNDX-5613
    • Clinical Trials
    • Publications
    • Compassionate Use
  • Investors
  • Collaboration
  • Join Us
  • Contact
Syndax
Contact Us
  • About
  • Patients & Caregivers
  • Pipeline
  • Investors
  • Collaboration
  • Join Us

Investors

Investors

Investor Relations

  • Investors
  • Press Releases
  • Events & Presentations
  • Corporate Governance
    • Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • Financial Information
    • SEC Filings
    • Annual Reports and Proxies
    • Quarterly Results
    • Key Ratios
  • Stock Information
    • Historic Stock Lookup
    • Investment Calculator
    • Analyst Coverage
    • Ownership Profile
  • FAQs
  • Contact Us

Press Releases

04.13.07

Syndax Pharmaceuticals Inc. Licenses Selective Histone Deacetylase Inhibitor MS-275

04.03.07

Syndax Pharmaceuticals Inc. closes $40 Million Series A Financing

Pagination

  • First page « first
  • Previous page ‹ previous
  • …
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Current page 17

Shareholder Tools

  • Printed Materials
  • Email Alerts
  • RSS
  • Print
  • Share
  • Search

  • Facebook
  • Google
  • LinkedIn
  • Twitter
  • RSS
© 2021 Syndax | Terms of Use | Privacy Policy | Site Map
  • About Us
  • Pipeline
  • News
  • Investors
  • Collaboration
  • Careers